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Diminished Bone Formation During Diabetic Fracture Healing Is Related to the
Premature Resorption of Cartilage Associated with Increased Osteoclast Activity
Abstract
Histological and molecular analysis of fracture healing in normal and diabetic animals showed
significantly enhanced removal of cartilage in diabetic animals. Increased cartilage turnover was
associated with elevated osteoclast numbers, a higher expression of genes that promote
osteoclastogenesis, and diminished primary bone formation.

Introduction
Diminished bone formation, an increased incidence of nonunions, and delayed fracture healing have been
observed in animal models and in patients with diabetes. Fracture healing is characterized by the
formation of a stabilizing callus in which cartilage is formed and then resorbed and replaced by bone. To
gain insight into how diabetes affects fracture healing, studies were carried out focusing on the impact of
diabetes on the transition from cartilage to bone.

Materials and Methods
A low-dose treatment protocol of streptozotocin in CD-1 mice was used to induce a type 1 diabetic
condition. After mice were hyperglycemic for 3 weeks, controlled closed simple transverse fractures of
the tibia were induced and fixed by intramedullary pins. Histomorphometric analysis of the tibias obtained
12, 16, and 22 days after fracture was performed across the fracture callus at 0.5 mm proximal and distal
increments using computer-assisted image analysis. Another group of 16-day samples were examined by
μCT. RNA was isolated from a separate set of animals, and the expression of genes that reflect the
formation and removal of cartilage and bone was measured by real-time PCR.

Results
Molecular analysis of collagen types II and X mRNA expression showed that cartilage formation was the
same during the initial period of callus formation. Histomorphometric analysis of day 12 fracture calluses
showed that callus size and cartilage area were also similar in normoglycemic and diabetic mice. In
contrast, on day 16, callus size, cartilage tissue, and new bone area were 2.0-, 4.4-, and 1.5-fold larger,
respectively, in the normoglycemic compared with the diabetic group (p < 0.05). Analysis of μCT images
indicated that the bone volume in the normoglycemic animals was 38% larger than in diabetic animals.
There were 78% more osteoclasts in the diabetic group compared with the normoglycemic group (p <
0.05) on day 16, consistent with the reduction in cartilage. Real-time PCR showed significantly elevated
levels of mRNA expression for TNF-α, macrophage-colony stimulating factor, RANKL, and vascular
endothelial growth factor-A in the diabetic group. Similarly, the mRNA encoding ADAMTS 4 and 5, major
aggrecanases that degrade cartilage, was also elevated in diabetic animals.

Conclusions
These results suggest that impaired fracture healing in diabetes is characterized by increased rates of
cartilage resorption. This premature loss of cartilage leads to a reduction in callus size and contributes to
decreased bone formation and mechanical strength frequently reported in diabetic fracture healing.
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Abstract
Histological and molecular analysis of fracture healing in normal and diabetic animals showed
significantly enhanced removal of cartilage in diabetic animals. Increased cartilage turnover was
associated with elevated osteoclast numbers, a higher expression of genes that promote
osteoclastogenesis, and diminished primary bone formation.
Introduction—Diminished bone formation, an increased incidence of nonunions, and delayed
fracture healing have been observed in animal models and in patients with diabetes. Fracture
healing is characterized by the formation of a stabilizing callus in which cartilage is formed and
then resorbed and replaced by bone. To gain insight into how diabetes affects fracture healing,
studies were carried out focusing on the impact of diabetes on the transition from cartilage to
bone.
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Materials and Methods—A low-dose treatment protocol of streptozotocin in CD-1 mice was
used to induce a type 1 diabetic condition. After mice were hyperglycemic for 3 weeks, controlled
closed simple transverse fractures of the tibia were induced and fixed by intramedullary pins.
Histomorphometric analysis of the tibias obtained 12, 16, and 22 days after fracture was
performed across the fracture callus at 0.5 mm proximal and distal increments using computerassisted image analysis. Another group of 16-day samples were examined by μCT. RNA was
isolated from a separate set of animals, and the expression of genes that reflect the formation and
removal of cartilage and bone was measured by real-time PCR.
Results—Molecular analysis of collagen types II and X mRNA expression showed that cartilage
formation was the same during the initial period of callus formation. Histomorphometric analysis
of day 12 fracture calluses showed that callus size and cartilage area were also similar in
normoglycemic and diabetic mice. In contrast, on day 16, callus size, cartilage tissue, and new
bone area were 2.0-, 4.4-, and 1.5-fold larger, respectively, in the normoglycemic compared with
the diabetic group (p < 0.05). Analysis of μCT images indicated that the bone volume in the
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normoglycemic animals was 38% larger than in diabetic animals. There were 78% more
osteoclasts in the diabetic group compared with the normoglycemic group (p < 0.05) on day 16,
consistent with the reduction in cartilage. Real-time PCR showed significantly elevated levels of
mRNA expression for TNF-α, macrophage-colony stimulating factor, RANKL, and vascular
endothelial growth factor-A in the diabetic group. Similarly, the mRNA encoding ADAMTS 4 and
5, major aggrecanases that degrade cartilage, was also elevated in diabetic animals.
Conclusions—These results suggest that impaired fracture healing in diabetes is characterized
by increased rates of cartilage resorption. This premature loss of cartilage leads to a reduction in
callus size and contributes to decreased bone formation and mechanical strength frequently
reported in diabetic fracture healing.
Keywords
cartilage; diabetes; endochondral bone; fracture; hyperglycemia; osteoclast

Introduction

NIH-PA Author Manuscript

Type 1 Diabetes has as one of its complications a decrease in BMD and inadequate bone
formation, resulting in osteopenia.(1,2) Serum alkaline phosphatase and osteocalcin levels are
significantly lower in type 1 diabetic patients, indicative of reduced bone formation.(2,3)
Diabetes has also been reported to increase bone resorption indicated by enhanced serum
levels of type I collagen cross-linked carboxy-terminal telopeptide (ICTP) and urinary levels
of deoxypyridinium cross-links.(2,4) The effect of os-teopenia is thought to contribute
significantly to the increased risk of both hip and long bone fractures.(5–7) Furthermore,
diabetes has been shown to significantly impair fracture healing. Case reports and clinical
studies have reported delayed union or increased healing time in diabetic subjects compared
with matched controls.(8,9)
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One of the best-characterized animal models to study the impact of diabetes on bone in rats
and mice is the induction of type 1 diabetes by streptozotocin. Treatment with streptozotocin
stimulates a host response that leads to destruction of the pancreatic β cells,
hypoinsulinemia, and hyperglycemia, with many features similar to type 1 diabetes.(10–12)
Studies using this animal model show that there is a significant decrease in BMD, BMC, and
serum osteocalcin levels in streptozotocin-induced diabetic animals.(13,14) Moreover, there is
a 20% decrease in biomechanical strength in both femurs and tibias.(14,15) BB rats, which
are spontaneously diabetic, show similar reductions in BMD, serum osteocalcin levels, and
mechanical properties.(16,17) Long bone fractures of spontaneously diabetic or
streptozotocin-induced diabetic animals exhibit smaller calluses with decreased bone
formation, decreased proliferation, and differentiation of osteoblastic cells and a 2-fold
reduction in the mechanical strength compared with matched controls.(18–21)
Although most studies have focused on bone, there also is evidence that diabetes impairs
cartilage formation during fracture healing through decreased chondrocyte differentiation
and proliferation.(19,20,22) Endochondral bone formation during fracture healing involves a
complex process of coordinated spatiotemporal events. The formation of the supporting
callus involves cartilage formation, which is a critical prerequisite to normal repair of long
bones. Therefore, it is conceivable that diabetes negatively impacts fracture healing by
affecting cartilage formation or resorption. To study further the impact of diabetes on
fracture repair, we undertook a detailed histological and molecular analysis focusing
specifically on the transition from cartilage to bone.
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Materials and Methods
Induction of type 1 diabetes
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The research was conducted in conformity with all Federal and USDA guidelines, as well as
an Institutional Animal Care & Use Committee (IACUC)–approved protocol. Eight-weekold, male CD-1 mice purchased from Charles River Laboratories (Wilmington, MA, USA)
were rendered diabetic by intraperitoneal injection of streptozotocin (40 mg/kg; Sigma, St
Louis, MO, USA) in 10 mM citrate buffer daily for 5 days.(23) Control mice were treated
identically with vehicle alone, 10 mM citrate buffer. Blood obtained from the tail was
assessed daily for glucose levels (Accu-Chek; Roche Diagnostics, Indianapolis, IN, USA)
for 1 week after the last injection and were considered to be diabetic when blood glucose
levels exceeded 250 mg/dl in two consecutive measurements. In addition, glycosylated
hemoglobin levels were measured at the time of death by Glyco-tek affinity chromatography
(Helena Laboratories, Beaumont, TX, USA). Blood glucose levels of diabetic animals
generally ranged from 300 to 550 mg/dl, with a mean of 411 mg/dl, and normoglycemic
mice from 110 to 160 mg/dl, with a mean of 142 mg/dl. Glycosylated hemoglobin in
diabetic animals ranged from 9.3% to 15.3% with a mean of 13.2%, whereas the values in
normoglycemic mice ranged from 5.1% to 6.7%, with a mean of 6%.
Tibial fractures
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All studies were performed on male mice that were diabetic for 3 weeks. A simple
transverse closed fracture of the left tibia was performed as previously described.(24,25)
Briefly, an incision was made on the medial aspect of the knee, and the articular surface of
the tibia was exposed. Access to the medullary canal was gained with a 25-gauge needle,
and a 27-gauge spinal needle was inserted for fixation. After closure of the incision, a
fracture was created by blunt trauma. Any fractures not consistent with standardized
placement criteria (mid-diaphyseal) or grossly comminuted were excluded. Animals were
subsequently killed at 12, 16, and 22 days after fracture. Tibias were harvested, and most of
the associated muscle and soft connective tissue was gently removed.
Histology and histomorphometric analysis
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The tibias with a small amount of surrounding muscle and soft tissues were fixed for 72 h in
cold 4% paraformaldehyde and decalcified for 2 weeks by incubation in cold Immunocal
(Decal Corp., Congers, NY, USA). After decalcification, the internal fixation pin was
removed, and tibias were embedded in paraffin, sectioned at 5 μm and prepared for staining.
Sectioning and histomorphometric measurements were performed according to
methodologies developed and validated in our laboratory.(26) Briefly cross-sectional
transverse sections were sampled at five sites along the long axis of the bone including the
fracture site itself, and 0.5 and 1.0 mm proximal and distal to the fracture site. The callus
area, new bone, and cartilage area were measured in sections stained with H&E, Van
Gieson/safranin-O, and safranin-O/fast green, respectively. The area of each tissue was
assessed by computer-assisted image analysis using Image ProPlus software (Media
Cybernetics, Silver Spring, MD, USA) as previously described.(27) Osteoclast formation was
determined by counting the number of multinucleated, TRACP+ cells lining bone or
cartilage as previously described.(27) For each data point, there were six to eight specimens.
Measurements were made by one examiner under blinded conditions, with the results
confirmed by a second examiner.
μCT and image analysis
Tibias from 11 diabetic and 9 normoglycemic mice at day 16 of healing were scanned
individually using a desktop microcomputed tomography system (Scanco μCT40; Scanco
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Medical, Basserdorf, Switzerland). Scans were performed at 70 kVp and 114 mA, with a
200-ms integration time and an isotropic voxel size of 12 μm. The scan axis coincided
nominally with the diaphyseal axis. The image data were analyzed using software provided
by the system manufacturer to quantify the bone volume of the fracture callus. The first step
in this analysis consisted of defining the outer boundary of the callus. This was done on
every 12-μm-thick slice along the length of the callus. Noise reduction in the image data
were achieved by applying a constrained, 3D Gaussian filter (sigma = 0.8, support = 1). A
fixed, global threshold was chosen that represented the transition in X-ray attenuation
between unmineralized and mineralized tissue.
Molecular markers of tissue degradation and synthesis
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After death, fracture calluses from diabetic and control animals were carefully dissected
from the tibia removing all muscle and noncallus tissue and immediately frozen in liquid
nitrogen. Total RNA was extracted with Trizol (Life Technologies, Rockville, MD, USA)
from pulverized frozen tissue and further purified by an RNAeasy MinElute cleanup kit
(Qiagen, Valencia, CA, USA). The concentration and integrity of the extracted RNA was
verified by 260 nm/280 nm spectrophotometry and denaturing agarose gel electrophoresis
with ethidium bromide staining. The mRNA levels of mediators, ADAMTS-type
metalloproteinases, MMP-13, and extracellular matrix molecules were assessed by real-time
PCR using primers and probe sets purchased from Applied Biosystems (Foster City, CA,
USA) as previously described.(28) For a given experiment RNA from nine tibias were
combined, and TaqMan reagents were used for first-strand cDNA synthesis and
amplification. Results were normalized with an 18S ribosomal primer and probe set. Each
experiment was performed three times, and the results from the three separate experiments
were combined to derive mean values. For a given gene, the expression for each group was
set relative to the value obtained for the normoglycemic control animals on day 12.
Statistical analysis
Data were presented as means and the statistical analysis between diabetic and nondiabetic
groups for a given parameter was established by Student's t-test, with p < 0.05 considered
statistically significant. ANOVA with Scheffe's posthoc test was used to analyze changes
within a group over time.

Results
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Histomorphometric analysis of fracture callus cross-sectional area indicated that there was
no significant difference between the diabetic and normoglycemic groups on day 12.
However, on day 16, the fracture callus in the diabetic group was 2-fold smaller than the
normoglycemic (p < 0.05; Fig. 1A). When the change in callus size was examined within a
group no statistically significant differences were noted over time.
To understand how diabetes affected the composition of the fracture callus bone and
cartilage was assessed. Normoglycemic and diabetic mice showed a 2.6- to 3-fold increase
in new bone accumulation in the calluses between days 12 and 16 (p < 0.05) after which
new bone accumulation remained constant (Fig. 1B). The level of new bone accumulation in
the diabetic group was significantly lower at each time-point ranging from 1.5 to 1.8 times
less in the diabetic compared with normal control animals (Fig. 1B; p < 0.05). The
difference in bone formation in the calluses of diabetic and normoglycemic groups on day
16 was confirmed by the μCT reconstructions. Bone volume calculated from the μCT
images was 38% higher in the normoglycemic group compared with the diabetic group (p <
0.05; Fig. 1C). An assessment of the quantity of bone as a percentage of the total callus in
histological sections showed that it was less in the diabetic group on day 12 (p < 0.05) but
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that at the two later time-points, the overall percentage of bone within the callus was similar
in diabetics and normoglycemics (Fig. 1D).
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During the initial phases of fracture healing endochondral bone formation provides rapid
stabilization of the fracture site. The areas that are first formed as cartilage establish the
spatial geometry of the callus and serve as templates on which new bone is formed.
Cartilage area was measured in safranin-O/fast green–stained sections from diabetic and
normal mice (Fig. 2A). Twelve days after fracture, there was a similar amount in both
groups (p > 0.05), but on day 16, the diabetic group was significantly lower than the control
group (p < 0.05). On day 22, the amount of total cartilage in both groups was small and
similar (p > 0.05). When assessed over time, there was a large and significant reduction in
cartilage area in the diabetic mice between days 12 and 16 (p < 0.05), whereas no significant
reduction occurred over this time period in the normoglycemic animals. Cartilage area did
decrease significantly in the control animals between days 16 and 22 (p < 0.05).
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To further examine the effect of diabetes on cartilage development, the percent area
occupied by cartilage within a callus was calculated (Fig. 2B). The highest percentage of
cartilage was found on day 12 and was equivalent in diabetic and normoglycemic groups (p
> 0.05). This parameter showed a steady reduction over time in the normoglycemic animals
but a sharp reduction in the diabetic mice from day 12 to 16. On day 16, the percent callus
represented by cartilage was 2.5 times less in the diabetic group than the normoglycemic
group (Fig. 2B; p < 0.05).
Changes in cartilage were examined at 0.5-mm intervals along the 2-mm length of the callus
(Figs. 2C–2E). On day 12, the area of cartilage was maximal at the center of the callus and
was equivalent in the diabetic and control groups at each site examined (Fig. 2C). At day 16,
the diabetic animals had significantly less cartilage (p < 0.05), particularly in the central
region of the callus (Fig. 3D). On day 22, there was a minimal amount of cartilage, and there
was no difference between the normoglycemic and the diabetic calluses (Fig. 2E).
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To study the anabolic activities of the bone and cartilage cells at the molecular level, realtime RT-PCR was carried out assessing the mRNA levels of collagen I, II, and X (Fig. 3).
The expression of collagen type II showed a significant reduction from day 12 to day 16 in
both normoglycemic and diabetic groups (p < 0.05), with no significant difference between
the two groups at any of the time-points (Fig. 3A; p > 0.05). We next examined the
expression of collagen X mRNA, a marker of hypertrophic chondrocytes that assesses
terminal differentiation of these cells and found it followed the same pattern of expression as
collagen type II with a significant decline from days 12 to 16 (Fig. 3B; p < 0.05). This
indicates that both groups are undergoing development at similar rates. Collagen type I
mRNA levels, a marker of osteogenic anabolic activity, also did not show statistical
differences between groups at any of the time-points (Fig. 3C; p > 0.05).
To further study cartilage resorption the number of TRACP+ cells was quantified. In the
diabetic group there was a 1.9-fold increase in osteoclasts from days 12 to 16 (p < 0.05),
whereas there were no statistical difference between these time-points in the normoglycemic
animals (Fig. 4A). The diabetic group had almost twice the number of osteoclasts found in
the normoglycemic group on day 16 (p < 0.05; Fig. 4A). Previous studies in our laboratory
had shown that, as the mineralized cartilage phase of the callus is resorbed, the distribution
of osteoclasts changes from the edge of the callus toward the center where cartilage remains
the longest.(26) Both diabetic and normoglycemic groups followed this trend over time (Figs.
4B–4D). The biggest difference occurred between the diabetic and normoglycemic mice on
day 16, where there were 2.1- to 2.5-fold more osteoclasts in the central regions of the callus
(at the fracture site and 0.5 mm proximal and distal) in the diabetic group (p < 0.05; Fig.
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4C). On day 22, the normoglycemic group and the diabetic group showed a similar pattern
of distribution and a similar number of osteoclasts (Fig. 4D).
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Real-time PCR was used to quantify the mRNA levels of several of the major known
mediators that regulate osteoclastogenesis. The expression of TNF-α in the diabetic group
increased 2.6-fold from day 12 to day 16 (p < 0.05), whereas in the normoglycemic group, it
did not (Fig. 5A). In contrast, the TNF-α mRNA levels increased in the normoglycemic
mice from day 16 to day 22 (p < 0.05). At every time-point, the values were significantly
higher in the diabetic group, 3.6-, 3.7-, and 1.5-fold compared with normoglycemic animals
(p < 0.05). When macrophage-colony stimulating factor (M-CSF) was assessed, the mRNA
levels were 2.2- and 2.3-fold higher in the diabetic than the normoglycemic animals on days
12 and 16 (p < 0.05; Fig. 5B). The RANKL was 2-fold higher in the diabetic compared with
normoglycemic group on days 12 and 16 (p < 0.05; Fig. 5C). The mRNA levels of both MCSF and RANKL did not show significant differences over time in the normoglycemic or
the diabetic groups. In contrast, the level of RANK increased from days 12 to 16 but
exhibited no difference between diabetics and normoglycemics (Fig. 5D). The expression of
TRAIL, a related TNF family member, was significantly enhanced in the diabetic group
between days 12 and 16 and was higher than normal control mice for both of these timepoints (p < 0.05; Fig. 5E). The normoglycemic group showed a significant increase from
days 16 to 22 (p < 0.05), making it equal to the diabetic group at day 22. No difference in
osteoprotegerin (OPG) was detected between diabetic and normoglycemic groups on days
12 and 16, whereas it was significantly reduced in the normal group from days 16 to 22,
making the diabetic group higher than the control group at the later time-point (p < 0.05;
Fig. 5F). Because vascular endothelial growth factors (VEGFs) are known to stimulate
osteoclastogenesis,(29,30) we assessed mRNA levels of VEGF-A and -C. VEGF-A was
found at highest levels on day 12, whereas VEGF-C was highest on day 22, suggesting that
VEGF-A may be important for osteoclastogenesis associated with early cartilage removal
(Fig. 5G). Moreover, VEGF-A was elevated 1.5-fold in the diabetic animals (p < 0.05) at
this time-point. VEGF-C showed the highest levels on day 22, suggesting that it might
participate in osseous remodeling (Fig. 5H). It was slightly higher than the diabetic group on
day 12 (p < 0.05).
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Another group of mRNA that was examined provides both a molecular confirmation of the
histological data that reflects the formation of osteoclastic cells and an examination of
mRNA that is expressed during the degradation of cartilage proteoglycans. The mRNA
levels of TRACP were significantly higher in the diabetic calluses compared with
normoglycemic animals on days 16 and 22 (p < 0.05; Fig. 6A). ADAMTS are a large family
of lytic enzymes (disintegrin-like and metallopeptidase [reprolysin type] with
thrombospondin-type 1 motifs) that degrade extracellular matrix proteins, including the
aggrecan proteoglycan found in cartilage.(31,32) The levels of both aggrecanase 2 (ADAMTS
5) and aggrecanase 1 (ADAMTS 4) were also significantly elevated in the diabetic group at
day 16 (p < 0.05; Figs. 6B and 6C). Matrix metaloproteinase-13 (MMP13) did not show a
significant difference between diabetic and normoglycemic mice on days 12 and 16 but was
1.5-fold higher in the diabetic group on day 22 (p < 0.05; Fig. 6B).

Discussion
Tibial fracture repair in the mouse follows a well-defined process of an initial inflammatory
response that is followed by the formation of cartilage, its mineralization, subsequent
resorption, and replacement with bone followed by bone remodeling.(25) Relatively little is
known about the impact of diabetes on the cartilage phase, which plays an important role in
the repair process because cartilage serves as a template for later bone formation.(33)
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Previous studies have shown that diabetic animals exhibit fracture calluses that are smaller
in size than those in normal animals,(18–22,34,35) consistent with our observations at the 16day time-point. However, it has also been reported that at an early time-point, 1 week, there
is no difference in callus size,(18) equivalent to our finding that normal and diabetic animals
had similar callus sizes at 12 days. This may be significant because it suggests that diabetes
affects the removal of cartilage, which may impact the transition from cartilage to bone.
In this study, we found that the amount of new bone was significantly less in diabetic mice
at all time-points, which confirms previous observations.(18,19,21,34) However, the
percentage of the callus consisting of bone was similar between normal and diabetic mice on
days 16 and 22. There also was no difference between diabetics and normals in the
expression of collagen I, II, or X, suggesting that the overall anabolic rate of chondrocytes
or osteoblasts is similar at that stage. The difference in the amount of bone is caused by a
smaller cartilage tissue anlage onto which the new bone is laid down. The diminished bone
volume caused by a smaller callus in the diabetic group is consistent with a decrease in
mechanical strength of the healing fracture callus caused by diabetes.(18–21)
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Two discrete types of resorption take place during fracture repair. The first occurs when
mineralized cartilage is removed, which we observed between days 12 and 16, and the
second involves secondary bone formation and remodeling, which occurs later.(25) Maes et
al.(36) showed that when osteoclast number is decreased during endochondral ossification,
cartilage is not efficiently removed. The diabetic condition is considerably different.
Diabetic calluses had double the number of osteoclasts and significantly less cartilage than
controls during the transition from cartilage to bone. This may be explained mechanistically
by significantly higher mRNA levels of TNF-α, M-CSF, RANKL, and to a lesser extent,
VEGF-A in the diabetic animals. These cytokines have been shown to induce differentiation
of bone marrow hematopoietic precursor cells into bone-resorbing osteoclasts(37) and are
associated with the resorption of mineralized cartilage.(38,39) In addition, we showed that
deficient TNF-α signaling causes an increased retention of cartilage.(40) It is striking that in
the diabetic animals the opposite is observed: increased TNF-α expression and the rapid and
efficient removal of cartilage. The TNF-related protein, TRAIL, which is also elevated in
diabetic mice, both induces chondrocyte apoptosis and binds to the RANKL antagonist,
OPG, and blocks its inhibitory effect on osteoclastogenesis and may thus promote cartilage
resorption.(41) VEGF is another mediator that plays an important role in the transition from
cartilage to bone in endochondral bone formation,(30,42) in part through enhanced
osteoclastogenesis.(29) In addition, VEGF is thought to play an important role in the
formation of new blood vessels, which follow osteoclast resorption of cartilage.(30) We
found that VEGF-A mRNA levels were high at the 12-day time-point and elevated in the
diabetic group on day 12, which could potentially contribute to the removal of cartilage.
Until recently, there has been relatively little understanding of the mechanisms involved in
the turnover of cartilage proteoglycan (aggrecan) in endochondral bone. Several studies
have shown that ADAMTS proteases are present in cartilage, particularly ADAMTS 4 and
5.(31,32,43,44) Our finding that ADAMTS 4 and 5 are higher in the diabetic group at day 16
would explain the greater removal of proteoglycan in the diabetic group. We found no
difference between normoglycemic and diabetic in mRNA levels of MMP13, which is
highly expressed during fracture healing and plays a major role in cartilage
remodeling.(32,45) However, this does not rule out the possibility that MMP13 activity is
higher in diabetic animals.
In conclusion, fracture repair occurs through a highly coordinated series of biological
processes that involve complex interplay among multiple cell types. These processes can be
altered as a consequence of diseases that affect bone. We report here that the primary effect
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of diabetes on cartilage is enhanced removal of cartilage. This may lead to a diminished
scaffold for new bone formation, and hence, a smaller callus size.
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FIG. 1.

Comparison of callus size and new bone formation in diabetic and normoglycemic mice. (A)
The callus was defined as the area within the peripheral fibrous capsule, excluding the
original cortical bone. Callus area was measured in H&E-stained cross-sections obtained
from five points sampled at 0.5-mm increments along a 2-mm length of the callus. The
individual measurements were summed to establish a value of total callus area per animal
for each of the three time-points examined. (B) The area of new bone within each callus was
measured in the same manner in van Gieson/safranin-O–stained sections. The individual
measurements were summed to establish a value for total new bone area per animal for each
of the three time-points examined. (C) The total volume of bone on day 16 as measured
from the μCT images. (D) Percentage of the callus consisting of newly formed bone. Data
are expressed as mean ± SE. *Significant difference between normal and diabetic groups (p
< 0.05). **Significant difference compared with the previous time-point within a group (p <
0.05).
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Comparison of cartilage area in diabetic and normoglycemic mice. (A) The area of cartilage
within each callus was measured in safranin-O/fast green–stained sections in the same
manner as described in Fig. 1. (B) Percentage of the callus consisting of cartilage. (C–E)
Cartilage area was measured at five points sampled at 0.5-mm increments along a 2-mm
length of the callus on days 12, 16, and 22, respectively. Data are expressed as mean ± SE.
*Significant difference between normal and diabetic groups (p < 0.05). **Significant
difference compared with the previous time-point within a group (p < 0.05).
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FIG. 3.

mRNA levels of cartilage and bone collagens. Total RNA from diabetic and normoglycemic
mice was extracted, purified, and evaluated by real-time PCR. Data are expressed relative to
the level of the normoglycemic group at day 12, which was set at 1. (A–C) mRNA
expression levels of collagen II, collagen X, and collagen I, respectively. Each collagen was
evaluated in three separate experiments using three mice each (n = 9), and the results are
expressed as mean ± SE. *Significant difference between normal and diabetic groups (p <
0.05). **Significant difference compared with the previous time-point within a group (p <
0.05).
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FIG. 4.

Comparison of osteoclast numbers in diabetic and normoglycemic mice. (A) The number of
osteoclasts within each callus was measured in TRACP-stained sections. For a given animal,
five points along a 2-mm length of the callus were sampled; the individual counts were
summed to establish a value of total osteoclast number per animal for each of the three timepoints. (B–D) Data for the individual counts obtained at the indicated intervals across the
callus at days 12, 16, and 22, respectively. Data are expressed as mean ± SE. *Significant
difference between normal and diabetic groups (p < 0.05). **Significant difference
compared with the previous time-point within a group (p < 0.05).
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FIG. 5.

mRNA levels of cytokines that regulate osteoclastogenesis. mRNA levels were measured
and normalized in the same manner as described in Fig. 3. (A–H) mRNA expression levels
of TNF, M-CSF, RANKL, RANK, TRAIL, OPG, VEGF-A, and VEGF-C, respectively.
Each cytokine was evaluated in three separate experiments using three mice each (n = 9),
and the results are expressed as mean ± SE. *Significant difference between normal and
diabetic groups (p < 0.05). **Significant difference compared with the previous time-point
within a group (p < 0.05).
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FIG. 6.

mRNA levels of enzymes that regulate tissue degradation. mRNA levels were measured and
normalized in the same manner as described in Fig. 3. (A–D) mRNA expression levels of
TRACP, ADAMTS-5, ADAMTS-4, and MMP13, respectively. Each enzyme was evaluated
in three separate experiments using three mice each (n = 9), and the results are expressed as
mean ± SE. *Significant difference between normal and diabetic groups (p < 0.05).
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